Increased risk of death in elderly people with dementia-related psychosis. ABILIFY ASIMTUFII and ABILIFY MAINTENA increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ABILIFY ASIMTUFII and ABILIFY MAINTENA are not for the treatment of people with dementia-related
memory loss (dementia). ABILIFY is not approved for the treatment of patients with dementia-related psychosis. Risk of suicidal thoughts or actions
ABILIFY ASIMTUFII and ABILIFY MAINTENA increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ABILIFY ASIMTUFII and ABILIFY MAINTENA are not for the treatment of people with dementia-related psychosis. Do not receive ABILIFY ASIMTUFII or ABILIFY MAINTENA if you are
Abilify is not approved for the treatment of dementia-related psychosis. Some individuals with dementia may, however, be treated with this medication. Discuss
memory loss (dementia). ABILIFY ASIMTUFII and ABILIFY MAINTENA are not for the treatment of people with dementia-related psychosis. Do not
ABILIFY ASIMTUFII and ABILIFY MAINTENA increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ABILIFY ASIMTUFII and ABILIFY MAINTENA are not for the treatment of people with dementia-related psychosis.
ABILIFY ASIMTUFII and ABILIFY MAINTENA are not for the treatment of people with dementia-related psychosis. Do not receive ABILIFY ASIMTUFII or ABILIFY MAINTENA
memory loss (dementia). Abilify Asimtufii is not for the treatment of people with dementia-related psychosis. Abilify Asimtufii and other
Abilify, also known as aripiprazole, is a treatment Increased mortality in elderly patients with dementia-related psychosis: Abilify
Comments